Drugs & Targets FDA investigating possible increased risk of death with lymphoma drug Ukoniq February 04, 2022Vol.48 No.05
In Brief Robert Califf’s confirmation as FDA commissioner clears Senate HELP Committee January 14, 2022Vol.48 No.02
Drugs & Targets FDA grants fast track designation for enobosarm in AR+ ER+ HER2- metastatic breast cancer January 14, 2022Vol.48 No.02
Drugs & Targets FDA clears IND for P-MUC1C-ALLO1, a fully allogeneic CAR T targeting multiple solid tumors January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Breakthrough Therapy designation for CLN-081 in locally advanced or metastatic EGFR-mutated NSCLC January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Fast Track designation for Reqorsa with Keytruda in NSCLC January 07, 2022Vol.48 No.01
Drugs & TargetsFree FDA approves Orencia for prevention of acute graft vs. host disease following unrelated donor HSCT December 17, 2021Vol.47 No.46
Drugs & Targets FDA approves Rituxan plus chemo for pediatric cancer indications December 10, 2021Vol.47 No.45
Drugs & Targets FDA approves FoundationOne CDx as companion diagnostic for BRAF inhibitor therapeutics in melanoma December 10, 2021Vol.47 No.45
